RU2016101630A3 - - Google Patents

Download PDF

Info

Publication number
RU2016101630A3
RU2016101630A3 RU2016101630A RU2016101630A RU2016101630A3 RU 2016101630 A3 RU2016101630 A3 RU 2016101630A3 RU 2016101630 A RU2016101630 A RU 2016101630A RU 2016101630 A RU2016101630 A RU 2016101630A RU 2016101630 A3 RU2016101630 A3 RU 2016101630A3
Authority
RU
Russia
Application number
RU2016101630A
Other versions
RU2016101630A (ru
RU2675851C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016101630A publication Critical patent/RU2016101630A/ru
Publication of RU2016101630A3 publication Critical patent/RU2016101630A3/ru
Application granted granted Critical
Publication of RU2675851C2 publication Critical patent/RU2675851C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2016101630A 2013-06-21 2014-06-20 Кристаллические формы свободного основания RU2675851C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361838105P 2013-06-21 2013-06-21
US61/838,105 2013-06-21
US201361919424P 2013-12-20 2013-12-20
US61/919,424 2013-12-20
PCT/US2014/043422 WO2014205354A2 (en) 2013-06-21 2014-06-20 Free base crystals

Publications (3)

Publication Number Publication Date
RU2016101630A RU2016101630A (ru) 2017-07-26
RU2016101630A3 true RU2016101630A3 (ru) 2018-03-21
RU2675851C2 RU2675851C2 (ru) 2018-12-25

Family

ID=52105535

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016101630A RU2675851C2 (ru) 2013-06-21 2014-06-20 Кристаллические формы свободного основания

Country Status (14)

Country Link
US (1) US9630971B2 (ru)
EP (2) EP3702358A1 (ru)
JP (2) JP6865036B2 (ru)
KR (2) KR102430126B1 (ru)
CN (3) CN110498800A (ru)
AU (1) AU2014284224B2 (ru)
BR (1) BR112015032132B1 (ru)
CA (1) CA2916393C (ru)
ES (1) ES2894770T3 (ru)
HK (1) HK1223848A1 (ru)
IL (2) IL243269B (ru)
MX (2) MX2015017972A (ru)
RU (1) RU2675851C2 (ru)
WO (1) WO2014205354A2 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
AR091507A1 (es) 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
RU2675851C2 (ru) 2013-06-21 2018-12-25 Интра-Селлулар Терапиз, Инк. Кристаллические формы свободного основания
WO2021226407A1 (en) * 2020-05-06 2021-11-11 Intra-Cellular Therapies, Inc. Free base crystals
WO2023034965A2 (en) * 2021-09-03 2023-03-09 Intra-Cellular Therapies, Inc. Co-crystals
WO2023147484A1 (en) * 2022-01-27 2023-08-03 Intra-Cellular Therapies, Inc. Novel compositions
WO2023233410A1 (en) * 2022-06-02 2023-12-07 Biosight Ltd. Crystalline form of aspacytarabine intermediate

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
US5471001A (en) * 1994-12-15 1995-11-28 E. I. Du Pont De Nemours And Company Crystallization of adipic acid
GB9624615D0 (en) * 1996-11-26 1997-01-15 Zeneca Ltd Chrystallisation process
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US7425567B2 (en) 2002-02-08 2008-09-16 Ono Pharmaceutical Co., Ltd. Piperidine derivative compounds and drugs containing the compounds as the active ingredient
WO2004087906A1 (en) * 2003-03-31 2004-10-14 Pfizer Products Inc. Crystal structure of 3',5'-cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof
AU2004268024B2 (en) * 2003-09-02 2007-07-12 Merck Sharp & Dohme Llc Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
CN101035759B (zh) * 2004-09-27 2011-06-15 阿卡蒂亚药品公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐的合成和晶形
AU2006255028B2 (en) 2005-06-06 2012-04-19 Intra-Cellular Therapies, Inc. Organic compounds
JP2010509399A (ja) 2006-11-13 2010-03-25 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規使用
HRP20131073T1 (hr) 2007-12-06 2014-01-31 Takeda Pharmaceutical Company Limited Organski spojevi
EP2370080A1 (en) * 2008-12-02 2011-10-05 University of Utah Research Foundation Pde1 as a target therapeutic in heart disease
BRPI0922808A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
MA32937B1 (fr) 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
ES2638912T3 (es) 2008-12-06 2017-10-24 Intra-Cellular Therapies, Inc. Compuestos orgánicos
EP2400970A4 (en) 2009-02-25 2012-07-18 Intra Cellular Therapies Inc PDE 1 INHIBITOR FOR OPHTHALMIC DISORDERS
WO2010132127A1 (en) 2009-05-13 2010-11-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2011043816A1 (en) 2009-10-08 2011-04-14 Intra-Cellular Therapies, Inc. Phosphodiesterase 1-targeting tracers and methods
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153138A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
AR091507A1 (es) 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
RU2675851C2 (ru) 2013-06-21 2018-12-25 Интра-Селлулар Терапиз, Инк. Кристаллические формы свободного основания

Also Published As

Publication number Publication date
BR112015032132B1 (pt) 2022-03-15
CA2916393A1 (en) 2014-12-24
JP2019189618A (ja) 2019-10-31
US20160145261A1 (en) 2016-05-26
BR112015032132A2 (pt) 2017-07-25
CN112851683A (zh) 2021-05-28
KR20210122890A (ko) 2021-10-12
JP6865036B2 (ja) 2021-04-28
RU2016101630A (ru) 2017-07-26
EP3010509A4 (en) 2016-11-23
MX2020001628A (es) 2020-07-13
EP3702358A1 (en) 2020-09-02
HK1223848A1 (zh) 2017-08-11
EP3010509A2 (en) 2016-04-27
AU2014284224A1 (en) 2016-02-11
KR102430126B1 (ko) 2022-08-05
IL243269B (en) 2019-06-30
WO2014205354A3 (en) 2015-05-28
IL243269A0 (en) 2016-02-29
AU2014284224B2 (en) 2019-08-01
US9630971B2 (en) 2017-04-25
IL267331A (en) 2019-08-29
ES2894770T3 (es) 2022-02-15
CN105658222A (zh) 2016-06-08
MX2015017972A (es) 2016-10-28
WO2014205354A2 (en) 2014-12-24
RU2675851C2 (ru) 2018-12-25
EP3010509B1 (en) 2021-07-28
KR20160040522A (ko) 2016-04-14
CN110498800A (zh) 2019-11-26
JP2016523258A (ja) 2016-08-08
CA2916393C (en) 2022-03-22

Similar Documents

Publication Publication Date Title
AP2016009275A0 (ru)
BR112015007533A2 (ru)
BR102016010778A2 (ru)
BR112014017733A2 (ru)
BR112014018502A2 (ru)
BR112014017739A2 (ru)
BR112014019326A2 (ru)
BR112014018516A2 (ru)
BR112014020341A2 (ru)
BR112014018480A2 (ru)
BR112014017855A2 (ru)
BR112014017765A2 (ru)
BR112014017669A2 (ru)
BR112015029866A2 (ru)
BR112014021878A2 (ru)
BR112014018468A2 (ru)
BR112014017901A2 (ru)
BR112014018207A2 (ru)
BR112014019204A2 (ru)
BR112015015948A2 (ru)
BR112014017722A2 (ru)
BR112014018483A2 (ru)
BR112014017794A2 (ru)
BR112014017653A2 (ru)
BR112014017601A2 (ru)